Patients with refractory prostate cancer previously treated with bicalutamide showed a decline in PSA levels following administration of flutamide: A report of two cases

Michihisa Saegusa, Ryuta Tanimoto, Hiroki Iguchi, Daisuke Manabe, Kenji Aramaki

Research output: Contribution to journalArticle

Abstract

We experienced 2 cases of refractory prostate cancer in patients previously treated with bicalutamide (BCL) where a decline in PSA levels was noted following the administration of flutamide (FLT). Case 1: A 61-year-old man was diagnosed with poorly differentiated prostate cancer (PC) with bone metastasis. Combined androgen blockade (CAB) comprising LH-RH analogue plus BCL was commenced. The level of PSA declined from 670 ng/ml to 1.92 ng/ml, but then gradually increased to 9.62 ng/ ml. We decided that the cancer was BCL-resistant and accordingly we stopped the administration of BCL. Because the PSA level continued to increase to 23.65 ng/ml 8 weeks after the cessation of BCL, FLT (250mg/day) was given. The level of PSA again declined to 7.75 ng/ml 9 weeks after the administration of FLT. However, re-elevation was detected 13 weeks later and 22 weeks later, the level of PSA was found to have increased to 17.07 ng/ml. Case 2: A 66-year-old man was diagnosed with poorly differentiated PC with bone and LN metastasis. Combined androgen blockade comprising LH-RH analogue plus BCL was commenced. The level of PSA showed a decline from over 100 ng/ml to 0.9 ng/ml 14 months later. However, after 3 consecutive elevations to 2.2 ng/ml, the administration of BCL was stopped. One month later, the PSA level had increased to 3.9 ng/ml, and so the administration of FLT (250mg/day) was started. After that, the PSA level declined to the nadir of 0.09 ng/ml, and 30 months later, the level is 0.23 ng/ml. Our experience suggests that FLT may be effective as a second-line therapy for refractory PC previously treated with BCL.

Original languageEnglish
Pages (from-to)195-198
Number of pages4
JournalNishinihon Journal of Urology
Volume67
Issue number4
Publication statusPublished - Apr 2005
Externally publishedYes

Fingerprint

Flutamide
Prostatic Neoplasms
Bone Neoplasms
Gonadotropin-Releasing Hormone
Androgens
Neoplasm Metastasis
bicalutamide

Keywords

  • Bicalutamide
  • Combined androgen blockade
  • Flutamide
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Patients with refractory prostate cancer previously treated with bicalutamide showed a decline in PSA levels following administration of flutamide : A report of two cases. / Saegusa, Michihisa; Tanimoto, Ryuta; Iguchi, Hiroki; Manabe, Daisuke; Aramaki, Kenji.

In: Nishinihon Journal of Urology, Vol. 67, No. 4, 04.2005, p. 195-198.

Research output: Contribution to journalArticle

Saegusa, Michihisa ; Tanimoto, Ryuta ; Iguchi, Hiroki ; Manabe, Daisuke ; Aramaki, Kenji. / Patients with refractory prostate cancer previously treated with bicalutamide showed a decline in PSA levels following administration of flutamide : A report of two cases. In: Nishinihon Journal of Urology. 2005 ; Vol. 67, No. 4. pp. 195-198.
@article{13a1f20f89dc496b8548b4d22f7d2867,
title = "Patients with refractory prostate cancer previously treated with bicalutamide showed a decline in PSA levels following administration of flutamide: A report of two cases",
abstract = "We experienced 2 cases of refractory prostate cancer in patients previously treated with bicalutamide (BCL) where a decline in PSA levels was noted following the administration of flutamide (FLT). Case 1: A 61-year-old man was diagnosed with poorly differentiated prostate cancer (PC) with bone metastasis. Combined androgen blockade (CAB) comprising LH-RH analogue plus BCL was commenced. The level of PSA declined from 670 ng/ml to 1.92 ng/ml, but then gradually increased to 9.62 ng/ ml. We decided that the cancer was BCL-resistant and accordingly we stopped the administration of BCL. Because the PSA level continued to increase to 23.65 ng/ml 8 weeks after the cessation of BCL, FLT (250mg/day) was given. The level of PSA again declined to 7.75 ng/ml 9 weeks after the administration of FLT. However, re-elevation was detected 13 weeks later and 22 weeks later, the level of PSA was found to have increased to 17.07 ng/ml. Case 2: A 66-year-old man was diagnosed with poorly differentiated PC with bone and LN metastasis. Combined androgen blockade comprising LH-RH analogue plus BCL was commenced. The level of PSA showed a decline from over 100 ng/ml to 0.9 ng/ml 14 months later. However, after 3 consecutive elevations to 2.2 ng/ml, the administration of BCL was stopped. One month later, the PSA level had increased to 3.9 ng/ml, and so the administration of FLT (250mg/day) was started. After that, the PSA level declined to the nadir of 0.09 ng/ml, and 30 months later, the level is 0.23 ng/ml. Our experience suggests that FLT may be effective as a second-line therapy for refractory PC previously treated with BCL.",
keywords = "Bicalutamide, Combined androgen blockade, Flutamide, Prostate cancer",
author = "Michihisa Saegusa and Ryuta Tanimoto and Hiroki Iguchi and Daisuke Manabe and Kenji Aramaki",
year = "2005",
month = "4",
language = "English",
volume = "67",
pages = "195--198",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "4",

}

TY - JOUR

T1 - Patients with refractory prostate cancer previously treated with bicalutamide showed a decline in PSA levels following administration of flutamide

T2 - A report of two cases

AU - Saegusa, Michihisa

AU - Tanimoto, Ryuta

AU - Iguchi, Hiroki

AU - Manabe, Daisuke

AU - Aramaki, Kenji

PY - 2005/4

Y1 - 2005/4

N2 - We experienced 2 cases of refractory prostate cancer in patients previously treated with bicalutamide (BCL) where a decline in PSA levels was noted following the administration of flutamide (FLT). Case 1: A 61-year-old man was diagnosed with poorly differentiated prostate cancer (PC) with bone metastasis. Combined androgen blockade (CAB) comprising LH-RH analogue plus BCL was commenced. The level of PSA declined from 670 ng/ml to 1.92 ng/ml, but then gradually increased to 9.62 ng/ ml. We decided that the cancer was BCL-resistant and accordingly we stopped the administration of BCL. Because the PSA level continued to increase to 23.65 ng/ml 8 weeks after the cessation of BCL, FLT (250mg/day) was given. The level of PSA again declined to 7.75 ng/ml 9 weeks after the administration of FLT. However, re-elevation was detected 13 weeks later and 22 weeks later, the level of PSA was found to have increased to 17.07 ng/ml. Case 2: A 66-year-old man was diagnosed with poorly differentiated PC with bone and LN metastasis. Combined androgen blockade comprising LH-RH analogue plus BCL was commenced. The level of PSA showed a decline from over 100 ng/ml to 0.9 ng/ml 14 months later. However, after 3 consecutive elevations to 2.2 ng/ml, the administration of BCL was stopped. One month later, the PSA level had increased to 3.9 ng/ml, and so the administration of FLT (250mg/day) was started. After that, the PSA level declined to the nadir of 0.09 ng/ml, and 30 months later, the level is 0.23 ng/ml. Our experience suggests that FLT may be effective as a second-line therapy for refractory PC previously treated with BCL.

AB - We experienced 2 cases of refractory prostate cancer in patients previously treated with bicalutamide (BCL) where a decline in PSA levels was noted following the administration of flutamide (FLT). Case 1: A 61-year-old man was diagnosed with poorly differentiated prostate cancer (PC) with bone metastasis. Combined androgen blockade (CAB) comprising LH-RH analogue plus BCL was commenced. The level of PSA declined from 670 ng/ml to 1.92 ng/ml, but then gradually increased to 9.62 ng/ ml. We decided that the cancer was BCL-resistant and accordingly we stopped the administration of BCL. Because the PSA level continued to increase to 23.65 ng/ml 8 weeks after the cessation of BCL, FLT (250mg/day) was given. The level of PSA again declined to 7.75 ng/ml 9 weeks after the administration of FLT. However, re-elevation was detected 13 weeks later and 22 weeks later, the level of PSA was found to have increased to 17.07 ng/ml. Case 2: A 66-year-old man was diagnosed with poorly differentiated PC with bone and LN metastasis. Combined androgen blockade comprising LH-RH analogue plus BCL was commenced. The level of PSA showed a decline from over 100 ng/ml to 0.9 ng/ml 14 months later. However, after 3 consecutive elevations to 2.2 ng/ml, the administration of BCL was stopped. One month later, the PSA level had increased to 3.9 ng/ml, and so the administration of FLT (250mg/day) was started. After that, the PSA level declined to the nadir of 0.09 ng/ml, and 30 months later, the level is 0.23 ng/ml. Our experience suggests that FLT may be effective as a second-line therapy for refractory PC previously treated with BCL.

KW - Bicalutamide

KW - Combined androgen blockade

KW - Flutamide

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=18244385223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244385223&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:18244385223

VL - 67

SP - 195

EP - 198

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 4

ER -